R

Roche

Global pharmaceuticals and diagnostics company

Business & Program Management Leader

Full-TimeUpdated on 10/23/2026Deadline 11/15/26
No salary listed
Mid
Welwyn, UK
In Person
Project & Program ManagementProgram Management

About the job

Requirements
  • Bring a solid track record of leading cross-functional delivery and embedding business or operational solutions in clinical development, medical affairs, or technology.
  • Have hands-on experience in program or project management and keep complex, cross-functional initiatives moving with discipline and clarity.
  • Have demonstrated experience leading change management efforts, including impact assessments, stakeholder engagement, adoption planning, and resistance management.
  • Have strong written and verbal communication skills and be able to synthesize complex project information into clear narratives for end users and senior leaders.
  • Be able to influence and connect with key stakeholders, gain alignment on outcomes, share information transparently and strategically, apply iteration and experimentation principles, and actively listen.
  • Be a systems thinker who connects project deliverables to organizational objectives and identifies dependencies, operational impacts, and adoption risks early.
  • Thrive in ambiguous, dynamic, matrixed environments with shared authority and accountability, using active listening, direct influence, and structured planning to drive action and delivery.
  • Be results-oriented in ambiguous environments, clarify objectives, and establish a clear, understandable plan or roadmap that drives teams toward action and impact.
  • Apply business knowledge and expertise to maximize company value, potentially including molecule development lifecycle, marketing application filings, transformational initiatives, large technology systems, and business process changes.
  • Be experienced using project management, change management, business management, or related tools, methodologies, and approaches to drive strategy development and achieve program, project, or function outcomes.
Responsibilities
  • Scope, plan, and execute project roadmaps, ensuring solutions are adopted to drive intended value realization within the agreed timeframe and iteratively.
  • Ensure consistent application of project delivery standards; manage day-to-day delivery mechanics, cross-functional coordination, and deliverable development.
  • Contribute to and manage team processes for developing critical deliverables.
  • Maintain accurate plans and program or project documentation, ensuring risks and issues are captured, tracked, and communicated promptly.
  • Capture, track, and mitigate operational, timeline, and execution risks; update risk registers and manage escalations promptly.
  • Prepare clear data updates and progress metrics for executive governance bodies, ensuring decision-making is based on accurate progress tracking.
  • Optimize team performance by establishing team norms, facilitating productive decision-making, and simplifying complex cross-functional workflows.
  • Design and deploy solution adoption frameworks so program and project deliverables are embedded into daily operational workflows across impacted business units.
  • Consider the end-user perspective during planning, perform impact assessments, map user journeys, and proactively address adoption barriers or resistance.
  • Establish and monitor user proficiency, adoption rates, and value-sustainment outcomes with Project Leads and Sponsors.
  • Define metrics and measure program and project outcomes with Project Sponsors and Leads.
  • Prepare leaders and stakeholders for change throughout execution and delivery with clear messaging about what is changing, why it is changing, and what it means for them; ensure impact assessments are accurate and stakeholders are informed.
  • Create transparent, targeted communication plans, including leadership briefings, project newsletters, and operational updates, explaining what is changing, why, and what it means for teams.
  • Equip managers and functional leaders with narratives, tools, and messaging to advocate for change and coach their teams through operational transitions.
Desired Qualifications
  • Experience or a strong understanding of Data Science and Analytics projects, digital curiosity, and broad knowledge of areas such as Agentic AI.
  • A demonstrated track record of leading and scaling Data Science, Advanced Analytics, or AI/ML initiatives.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 22nd, 2026
Roche reaffirms outlook as Q3 sales rise 7% to $19.6B, but growth doubts linger

Roche reaffirmed its 2025 outlook on Thursday and beat third-quarter sales expectations, but questions about its long-term growth remain. Group sales rose 7% to 16.1 billion Swiss francs (about $19.6 billion), ahead of the 15.8 billion franc consensus estimate. Jefferies analyst Michael Leuchten said a new resource planning system boosted revenue, making the results "cosmetically ahead." Roche still expects group sales growth in the "mid single digit range" and did not raise guidance. Sales of allergy and asthma drug Xolair reached only 848 million francs, well below estimates. A copycat version launched in the US this month, and Ocrevus and Tecentriq face generic competition by 2030. Roche is counting on its breast cancer pill giredestrant, which awaits a US Food and Drug Administration decision by December 18, and on obesity drugs. It says the products could together reach $9 billion in peak annual sales.

CNBC
Oct 22nd, 2026
Roche CEO presses Germany on growth strategy as drugmaker pauses investment there

Roche chief executive officer Thomas Schinecker has challenged Germany over its growth strategy, saying pharmaceutical firms are "the industry they need to bet on." Schinecker discussed the company's third-quarter earnings and its recent expansion in China. He also outlined recent pharmaceutical developments at the business. He explained why Roche has paused investment in Germany.

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.